Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606030 · ClinicalTrials.gov registry record · NA
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
A NA study of Lymphedema and Edema, sponsored by Fibralign Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04606030: Recruiting NA study of Lymphedema and Edema, sponsored by Fibralign Corporation.
NCT04606030 is a NA study of Lymphedema and Edema that is actively recruiting participants, run by Fibralign Corporation. The registered enrollment target is 60 participants, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04606030, a NA study of Lymphedema and Edema, is actively recruiting participants, sponsored by Fibralign Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.
Primary Outcome
Change in % of (excess) limb volume in the intervention group relative to control group
Conditions Studied
Interventions
- DEVICE BioBridge® Collagen Matrix
- PROCEDURE Vascularized Lymph Node Transfer (VLNT)
Study Locations (2)
Illinois
- The University of Chicago Biological Sciences Division/University of Chicago Medical Center - Chicago
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2025-12-30 |
| Phase | NA |
What NCT04606030 shows while recruiting
NCT04606030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which BioBridge® Collagen Matrix is the first listed.
NCT04606030 reports a single indexed study location in Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT04606030 about?
NCT04606030 is a clinical study titled "LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)". To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.
What is the current status of trial NCT04606030?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2020-10-26. Estimated completion is 2025-12-30.
What conditions does trial NCT04606030 study?
This clinical trial studies the following conditions: Lymphedema, Edema.
What interventions are being tested in trial NCT04606030?
The interventions under investigation include: BioBridge® Collagen Matrix (DEVICE), Vascularized Lymph Node Transfer (VLNT) (PROCEDURE).
Who is sponsoring clinical trial NCT04606030?
This trial is sponsored by Fibralign Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606030 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04606030's enrollment target sits among peer trials
60 26th of 34 higher than 8 of 34 other Lymphedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)
RECRUITING · NA
-
Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema/Phlebolymphedema
RECRUITING · NA
-
A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
RECRUITING · NA
-
Pedal Pump and Leg Lymphedema
RECRUITING · NA
-
Comparing Two Ways to Manage Head and Neck Lymphedema
RECRUITING · NA
-
LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI